MaxCyte (NASDAQ:MXCT) Rating Lowered to “Sell” at Wall Street Zen

MaxCyte (NASDAQ:MXCT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Monday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, MaxCyte has an average rating of “Hold” and an average target price of $6.00.

MaxCyte Stock Up 0.3%

MXCT opened at $0.76 on Monday. MaxCyte has a 52-week low of $0.64 and a 52-week high of $3.17. The firm has a market capitalization of $80.54 million, a P/E ratio of -1.72 and a beta of 1.22. The firm’s 50 day moving average is $0.90 and its 200-day moving average is $1.34.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its position in shares of MaxCyte by 39.5% during the third quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock worth $57,000 after acquiring an additional 10,263 shares during the last quarter. Kwmg LLC increased its stake in shares of MaxCyte by 75.8% during the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after acquiring an additional 11,135 shares during the period. Prudential Financial Inc. acquired a new position in shares of MaxCyte during the 2nd quarter valued at $26,000. State of Wyoming bought a new stake in MaxCyte in the second quarter worth about $38,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of MaxCyte in the 2nd quarter worth approximately $40,000. 68.81% of the stock is currently owned by institutional investors.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.